IL191277A - Pharmaceutical Vascular Injury Remedy, Containing Hematopoietic Camotactic Stem Cell Product Containing Monoclonal Cell-Rich Cells; CD34 + Method for Preparing and Using the Pharmaceutical Preparation - Google Patents
Pharmaceutical Vascular Injury Remedy, Containing Hematopoietic Camotactic Stem Cell Product Containing Monoclonal Cell-Rich Cells; CD34 + Method for Preparing and Using the Pharmaceutical PreparationInfo
- Publication number
- IL191277A IL191277A IL191277A IL19127708A IL191277A IL 191277 A IL191277 A IL 191277A IL 191277 A IL191277 A IL 191277A IL 19127708 A IL19127708 A IL 19127708A IL 191277 A IL191277 A IL 191277A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- pharmaceutical composition
- catheter
- cxcr
- cell product
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims description 517
- 230000003399 chemotactic effect Effects 0.000 title claims description 197
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims description 150
- 238000000034 method Methods 0.000 title claims description 126
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 92
- 238000002360 preparation method Methods 0.000 title claims description 23
- 208000024248 Vascular System injury Diseases 0.000 title claims description 19
- 208000012339 Vascular injury Diseases 0.000 title claims description 19
- 239000003814 drug Substances 0.000 title claims description 11
- 210000005087 mononuclear cell Anatomy 0.000 title claims description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 337
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 337
- 239000000047 product Substances 0.000 claims description 255
- 238000001802 infusion Methods 0.000 claims description 85
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 83
- 210000001185 bone marrow Anatomy 0.000 claims description 82
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 76
- 230000003389 potentiating effect Effects 0.000 claims description 74
- 238000003306 harvesting Methods 0.000 claims description 61
- 230000001404 mediated effect Effects 0.000 claims description 56
- 210000002966 serum Anatomy 0.000 claims description 42
- 230000003394 haemopoietic effect Effects 0.000 claims description 41
- 238000000338 in vitro Methods 0.000 claims description 41
- 230000000747 cardiac effect Effects 0.000 claims description 33
- 206010061216 Infarction Diseases 0.000 claims description 31
- 238000012545 processing Methods 0.000 claims description 31
- 230000036512 infertility Effects 0.000 claims description 28
- 239000006228 supernatant Substances 0.000 claims description 24
- 238000011010 flushing procedure Methods 0.000 claims description 22
- 230000007574 infarction Effects 0.000 claims description 22
- 239000008188 pellet Substances 0.000 claims description 22
- 210000001367 artery Anatomy 0.000 claims description 21
- 102000004127 Cytokines Human genes 0.000 claims description 20
- 108090000695 Cytokines Proteins 0.000 claims description 20
- 210000004165 myocardium Anatomy 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 229920000669 heparin Polymers 0.000 claims description 16
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 14
- 229960002897 heparin Drugs 0.000 claims description 14
- 230000002107 myocardial effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000002757 inflammatory effect Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 11
- 230000000087 stabilizing effect Effects 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 9
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 229940127090 anticoagulant agent Drugs 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 5
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- 239000004004 anti-anginal agent Substances 0.000 claims description 4
- 229940124345 antianginal agent Drugs 0.000 claims description 4
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 4
- 229940097320 beta blocking agent Drugs 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- 230000000260 hypercholesteremic effect Effects 0.000 claims description 4
- 239000002550 vasoactive agent Substances 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 3
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000036573 scar formation Effects 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 description 35
- 210000003743 erythrocyte Anatomy 0.000 description 30
- 230000001617 migratory effect Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 208000010125 myocardial infarction Diseases 0.000 description 27
- 230000010412 perfusion Effects 0.000 description 27
- 210000000265 leukocyte Anatomy 0.000 description 26
- 230000006870 function Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 230000003833 cell viability Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 230000004087 circulation Effects 0.000 description 19
- 230000004217 heart function Effects 0.000 description 19
- 238000011084 recovery Methods 0.000 description 18
- 230000000717 retained effect Effects 0.000 description 18
- 230000006378 damage Effects 0.000 description 17
- 230000002861 ventricular Effects 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 206010054880 Vascular insufficiency Diseases 0.000 description 15
- 208000023577 vascular insufficiency disease Diseases 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 230000008439 repair process Effects 0.000 description 13
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 10
- 210000004351 coronary vessel Anatomy 0.000 description 10
- 238000002592 echocardiography Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000003978 infusion fluid Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 8
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 8
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 8
- 102000004903 Troponin Human genes 0.000 description 8
- 108090001027 Troponin Proteins 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000004820 blood count Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000000250 revascularization Effects 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 7
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000001332 colony forming effect Effects 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- -1 Sca-1 Proteins 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 238000002565 electrocardiography Methods 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000010967 transthoracic echocardiography Methods 0.000 description 5
- 239000001974 tryptic soy broth Substances 0.000 description 5
- 108010050327 trypticase-soy broth Proteins 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 208000012661 Dyskinesia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 101100462505 Mus musculus Pik3c2a gene Proteins 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 208000033774 Ventricular Remodeling Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000035605 chemotaxis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 238000007449 liver function test Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000004526 pharmaceutical effect Effects 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 238000013190 sterility testing Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- RBSXHDIPCIWOMG-UHFFFAOYSA-N 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea Chemical compound CCS(=O)(=O)C=1N=C2C=CC=CN2C=1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 RBSXHDIPCIWOMG-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 206010001541 Akinesia Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010011086 Coronary artery occlusion Diseases 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
- 206010020651 Hyperkinesia Diseases 0.000 description 2
- 208000000269 Hyperkinesis Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101150052863 THY1 gene Proteins 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 210000002302 brachial artery Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 230000003483 hypokinetic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000013146 percutaneous coronary intervention Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000009262 vessel revascularization Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000212977 Andira Species 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical class CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000036586 afterload Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000000876 binomial test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019625 fat content Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940009600 gammagard Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000025628 hematopoietic stem cell migration Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000947 motile cell Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000007409 radiographic assessment Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Developmental Biology & Embryology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73415105P | 2005-11-07 | 2005-11-07 | |
| PCT/US2006/041536 WO2007055905A2 (en) | 2005-11-07 | 2006-10-24 | Compositions and methods of vascular injury repair |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL191277A true IL191277A (en) | 2014-06-30 |
Family
ID=38023762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL191277A IL191277A (en) | 2005-11-07 | 2008-05-06 | Pharmaceutical Vascular Injury Remedy, Containing Hematopoietic Camotactic Stem Cell Product Containing Monoclonal Cell-Rich Cells; CD34 + Method for Preparing and Using the Pharmaceutical Preparation |
| IL232997A IL232997A (en) | 2005-11-07 | 2014-06-08 | Sterile Pharmacist's Composition for Vascular Injury Caused by Vascular Failure Containing Stem Cell Product |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL232997A IL232997A (en) | 2005-11-07 | 2014-06-08 | Sterile Pharmacist's Composition for Vascular Injury Caused by Vascular Failure Containing Stem Cell Product |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7794705B2 (https=) |
| EP (2) | EP1951864B1 (https=) |
| JP (1) | JP5087551B2 (https=) |
| CA (1) | CA2628712C (https=) |
| DK (2) | DK1951864T3 (https=) |
| ES (2) | ES2486300T4 (https=) |
| IL (2) | IL191277A (https=) |
| MY (1) | MY147516A (https=) |
| PL (2) | PL2441461T3 (https=) |
| PT (2) | PT2441461E (https=) |
| SI (2) | SI2441461T1 (https=) |
| WO (1) | WO2007055905A2 (https=) |
| ZA (1) | ZA200804711B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637005B2 (en) | 2005-11-07 | 2014-01-28 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
| US20110076255A1 (en) | 2005-11-07 | 2011-03-31 | Pecora Andrew L | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
| WO2008056368A2 (en) * | 2006-11-09 | 2008-05-15 | Gamida-Cell Ltd. | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases |
| US8137968B2 (en) * | 2007-02-28 | 2012-03-20 | The Board Of Trustees Of The University Of Illinois | Selected endothelial progenitor cells and methods for use |
| BRPI0919020B8 (pt) * | 2008-09-12 | 2021-05-25 | Cryopraxis Criobiologia Ltda | uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris |
| CN102245189B (zh) * | 2008-12-03 | 2015-06-17 | 阿莫塞特公司 | 改善梗死区灌注的组合物以及血管损伤修复方法 |
| JP5709880B2 (ja) * | 2009-10-23 | 2015-04-30 | アモーサイト インコーポレイテッド | 血管の機能不全による進行性心筋傷害治療のための組成物および方法 |
| US9533010B2 (en) | 2011-10-31 | 2017-01-03 | Amorcyte, Llc | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
| EP2943206A4 (en) * | 2013-01-12 | 2017-01-04 | Cesca Therapeutics Inc. | Rapid infusion of autologous bone marrow derived stem cells |
| ES2927175T3 (es) | 2013-02-12 | 2022-11-03 | Reneuron Ltd | Método de producción de micropartículas |
| US20140313321A1 (en) | 2013-02-13 | 2014-10-23 | SeeScan, Inc. | Optical ground tracking apparatus, systems, and methods |
| WO2016006782A1 (ko) * | 2014-07-08 | 2016-01-14 | 라정찬 | 줄기세포의 보관 안정성 증진용 조성물 |
| US11504335B2 (en) | 2018-06-18 | 2022-11-22 | University Of Kentucky Research Foundation | Increased cell retention in diseased site when cells encapsulated in gelatin methacrylate and polyethylene glycol diacrylate hydrogels |
| WO2020154664A1 (en) * | 2019-01-25 | 2020-07-30 | The Johns Hopkins University | Predicting atrial fibrillation recurrence after pulmonary vein isolation using simulations of patient-specific magnetic resonance imaging models and machine learning |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| EP4228406A4 (en) | 2020-10-14 | 2024-11-13 | Ossium Health, Inc. | SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION |
| CN117279650A (zh) | 2020-12-18 | 2023-12-22 | 奥瑟姆健康公司 | 细胞治疗方法 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055556A (en) | 1981-10-06 | 1991-10-08 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Fluorescent conjugates for analysis of molecules and cells |
| US4859582A (en) | 1981-10-06 | 1989-08-22 | The Board Of Trustees Of The Leland Stanford Jr. University | Fluorescent conjugates for analysis of molecules and cells |
| US4520110A (en) | 1981-10-06 | 1985-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor |
| EP0076695B1 (en) | 1981-10-06 | 1985-02-20 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent conjugates for analysis of molecules and cells |
| US4714680B1 (en) | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
| US5130144B1 (en) | 1984-02-06 | 1995-08-15 | Univ Johns Hopkins | Human stem cells and monoclonal antibodies |
| US4965204A (en) | 1984-02-06 | 1990-10-23 | The Johns Hopkins University | Human stem cells and monoclonal antibodies |
| US5656493A (en) | 1985-03-28 | 1997-08-12 | The Perkin-Elmer Corporation | System for automated performance of the polymerase chain reaction |
| US5333675C1 (en) | 1986-02-25 | 2001-05-01 | Perkin Elmer Corp | Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps |
| FR2596413B1 (fr) | 1986-03-27 | 1988-06-10 | Merieux Inst | Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application |
| US5627027A (en) | 1986-04-18 | 1997-05-06 | Carnegie Mellon University | Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods |
| US5268486A (en) | 1986-04-18 | 1993-12-07 | Carnegie-Mellon Unversity | Method for labeling and detecting materials employing arylsulfonate cyanine dyes |
| US5569587A (en) | 1986-04-18 | 1996-10-29 | Carnegie Mellon University | Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes |
| US4876190A (en) | 1987-10-21 | 1989-10-24 | Becton Dickinson & Company | Peridinin-chlorophyll complex as fluorescent label |
| US5536475A (en) | 1988-10-11 | 1996-07-16 | Baxter International Inc. | Apparatus for magnetic cell separation |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5723218A (en) | 1990-04-16 | 1998-03-03 | Molecular Probes, Inc. | Dipyrrometheneboron difluoride labeled flourescent microparticles |
| US5726152A (en) | 1990-09-21 | 1998-03-10 | Merck & Co., Inc. | Vascular endothelial cell growth factor II |
| US5234824A (en) | 1990-11-13 | 1993-08-10 | Specialty Laboratories, Inc. | Rapid purification of DNA |
| US5187083A (en) | 1990-11-13 | 1993-02-16 | Specialty Laboratories, Inc. | Rapid purification of DNA |
| DE69229454T2 (de) | 1991-03-28 | 2000-01-05 | Merck & Co., Inc. | Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| US5776709A (en) | 1991-08-28 | 1998-07-07 | Becton Dickinson And Company | Method for preparation and analysis of leukocytes in whole blood |
| WO1993025216A1 (en) | 1992-06-08 | 1993-12-23 | Becton, Dickinson And Company | Human primitive stem cells |
| CA2170357A1 (en) | 1993-08-25 | 1995-03-02 | David Digiusto | Method for producing a highly enriched population of hematopoietic stem cells |
| US5415636A (en) | 1994-04-13 | 1995-05-16 | Schneider (Usa) Inc | Dilation-drug delivery catheter |
| US5968753A (en) | 1994-06-14 | 1999-10-19 | Nexell Therapeutics, Inc. | Positive and positive/negative cell selection mediated by peptide release |
| US20030113304A1 (en) | 1995-06-07 | 2003-06-19 | The Trustees Of Columbia University | Selective tissue site revascularization by combined focal injury and hematopoietic stem cell introduction |
| US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US8075880B2 (en) | 1999-01-11 | 2011-12-13 | Steward St. Elizabeth's Medical Center Of Boston, Inc. | Compositions and methods for regulating angiogenesis |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| CA2311729A1 (en) | 1998-01-23 | 1999-07-29 | Imclone Systems Incorporated | Purified populations of stem cells |
| US6676937B1 (en) | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
| US7115417B1 (en) | 1998-05-01 | 2006-10-03 | Chancellor Michael B | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof |
| CA2330208A1 (en) | 1998-05-29 | 1999-12-02 | Thomas Jefferson University | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals |
| IL125532A0 (en) | 1998-07-27 | 1999-03-12 | Yeda Res & Dev | Hematopoietic cell composition for use in transplantation |
| CA2341754A1 (en) | 1998-08-31 | 2000-03-09 | New York University | Stem cells bearing an fgf receptor on the cell surface |
| US6287265B1 (en) * | 1999-06-23 | 2001-09-11 | Cindy L. Gleason | Blood collection kit |
| US8075881B2 (en) | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
| AU1100001A (en) | 1999-10-29 | 2001-05-14 | Children's Hospital Of Los Angeles | Gammac negative hematopoietic progenitor cells |
| US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
| AU2001250966A1 (en) | 2000-03-23 | 2001-10-03 | Stem Cells, Inc. | Pluripotential stem cells |
| CA2412436C (en) | 2000-06-05 | 2013-05-21 | The Trustees Of Columbia University In The City Of New York | Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| US6878371B2 (en) * | 2000-07-26 | 2005-04-12 | Boston Scientific Scimed, Inc. | Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
| WO2002013760A2 (en) | 2000-07-31 | 2002-02-21 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU2001284695A1 (en) | 2000-07-31 | 2002-02-13 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US7862810B2 (en) | 2000-07-31 | 2011-01-04 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| CA2421834A1 (en) | 2000-09-11 | 2002-03-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Use of carp inhibitors for the treatment of heart diseases |
| JP2005508831A (ja) | 2000-10-02 | 2005-04-07 | ザ スクリプス リサーチ インスティテュート | 血管新生促進のための方法および組成物 |
| FR2819265B1 (fr) | 2001-01-10 | 2004-01-02 | Centre Nat Rech Scient | Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques |
| EP1361896A2 (en) | 2001-01-23 | 2003-11-19 | Boston Scientific Corporation | Localized myocardial injection method for treating ischemic myocardium |
| JP2004536794A (ja) | 2001-04-09 | 2004-12-09 | メドトロニック、インコーポレイテッド | マイクロ遠心機を用いる血液成分の分離方法及びその使用法 |
| ITTO20010517A1 (it) | 2001-05-31 | 2002-12-01 | Giulio Alessandri | Cellule progenitrici vascolari umane. |
| WO2003013570A1 (en) | 2001-08-09 | 2003-02-20 | Cornell Research Foundation, Inc. | Platelet-derived growth factor protection of cardiac myocardium |
| US9969980B2 (en) | 2001-09-21 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
| AU2002353465B2 (en) * | 2001-11-21 | 2008-10-16 | Yeda Research And Development Co. Ltd. | Process for the manufacture of human mononuclear phagocytic leukocytes |
| US20050095228A1 (en) | 2001-12-07 | 2005-05-05 | Fraser John K. | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders |
| EP1465983B1 (en) | 2001-12-21 | 2010-03-31 | Immunex Corporation | Endothelial stem cells, populations, methods of isolation and use thereof |
| AU2003217271A1 (en) | 2002-01-29 | 2003-09-02 | A. Mark Colb | Endothelialization of vascular surfaces |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| EP1551955A4 (en) | 2002-07-16 | 2006-11-29 | Yissum Res Dev Co | METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION |
| PL216193B1 (pl) | 2002-07-25 | 2014-03-31 | Scripps Research Inst | Wyizolowana, ssacza, pochodząca ze szpiku kostnego linia populacji niezróżnicowanych krwiotwórczych komórek macierzystych |
| AU2003270051A1 (en) | 2002-08-29 | 2004-03-19 | Baylor College Of Medicine | Heart derived cells for cardiac repair |
| US9969977B2 (en) | 2002-09-20 | 2018-05-15 | Garnet Biotherapeutics | Cell populations which co-express CD49c and CD90 |
| US20040136973A1 (en) | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| WO2004052177A2 (en) | 2002-12-05 | 2004-06-24 | Case Western Reserve University | Cell-based therapies for ischemia |
| US7470538B2 (en) * | 2002-12-05 | 2008-12-30 | Case Western Reserve University | Cell-based therapies for ischemia |
| US6995087B2 (en) * | 2002-12-23 | 2006-02-07 | Chartered Semiconductor Manufacturing Ltd. | Integrated circuit with simultaneous fabrication of dual damascene via and trench |
| US20040197310A1 (en) | 2003-02-12 | 2004-10-07 | Sanberg Paul R. | Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction |
| CN1770976A (zh) | 2003-02-13 | 2006-05-10 | 人类起源公司 | 利用脐带血治疗患有疾病、紊乱或状况的个体的用途 |
| US7863043B2 (en) | 2004-02-11 | 2011-01-04 | Aldagen, Inc. | Stem cell populations and methods of use |
| US20050232905A1 (en) | 2004-03-26 | 2005-10-20 | Yeh Edward T | Use of peripheral blood cells for cardiac regeneration |
| US7910755B2 (en) | 2004-09-29 | 2011-03-22 | Harbor Biosciences, Inc. | Stem cell expansion and uses |
| JP2006115771A (ja) | 2004-10-22 | 2006-05-11 | Kyoto Univ | 骨格筋由来の心筋幹細胞 |
| WO2006093860A2 (en) | 2005-02-28 | 2006-09-08 | Regenetech, Inc. | Method and composition for repairing heart tissue |
| WO2006121532A2 (en) | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
-
2006
- 2006-10-24 MY MYPI20081452A patent/MY147516A/en unknown
- 2006-10-24 WO PCT/US2006/041536 patent/WO2007055905A2/en not_active Ceased
- 2006-10-24 SI SI200631813T patent/SI2441461T1/sl unknown
- 2006-10-24 ES ES11008854T patent/ES2486300T4/es active Active
- 2006-10-24 SI SI200631812T patent/SI1951864T1/sl unknown
- 2006-10-24 DK DK06836498.3T patent/DK1951864T3/da active
- 2006-10-24 DK DK11008854.9T patent/DK2441461T3/da active
- 2006-10-24 ES ES06836498.3T patent/ES2485387T3/es active Active
- 2006-10-24 EP EP06836498.3A patent/EP1951864B1/en active Active
- 2006-10-24 JP JP2008540041A patent/JP5087551B2/ja not_active Expired - Fee Related
- 2006-10-24 EP EP11008854.9A patent/EP2441461B1/en active Active
- 2006-10-24 CA CA2628712A patent/CA2628712C/en active Active
- 2006-10-24 PL PL11008854T patent/PL2441461T3/pl unknown
- 2006-10-24 PT PT110088549T patent/PT2441461E/pt unknown
- 2006-10-24 PT PT68364983T patent/PT1951864E/pt unknown
- 2006-10-24 US US11/552,396 patent/US7794705B2/en active Active
- 2006-10-24 PL PL06836498T patent/PL1951864T3/pl unknown
-
2008
- 2008-05-06 IL IL191277A patent/IL191277A/en not_active IP Right Cessation
- 2008-05-30 ZA ZA200804711A patent/ZA200804711B/xx unknown
-
2009
- 2009-03-10 US US12/401,291 patent/US8088370B2/en active Active
-
2014
- 2014-06-08 IL IL232997A patent/IL232997A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1951864A4 (en) | 2009-04-29 |
| ES2485387T3 (es) | 2014-08-13 |
| EP1951864A2 (en) | 2008-08-06 |
| PT1951864E (pt) | 2014-08-27 |
| ZA200804711B (en) | 2009-10-28 |
| PT2441461E (pt) | 2014-08-26 |
| MY147516A (en) | 2012-12-31 |
| CA2628712A1 (en) | 2007-05-18 |
| IL232997A (en) | 2016-06-30 |
| DK1951864T3 (da) | 2014-07-28 |
| EP2441461A1 (en) | 2012-04-18 |
| US20090226402A1 (en) | 2009-09-10 |
| PL2441461T3 (pl) | 2014-11-28 |
| EP1951864B1 (en) | 2014-05-07 |
| US20070105217A1 (en) | 2007-05-10 |
| JP2009514950A (ja) | 2009-04-09 |
| US7794705B2 (en) | 2010-09-14 |
| SI1951864T1 (sl) | 2014-09-30 |
| US8088370B2 (en) | 2012-01-03 |
| PL1951864T3 (pl) | 2014-10-31 |
| EP2441461B1 (en) | 2014-05-07 |
| JP5087551B2 (ja) | 2012-12-05 |
| DK2441461T3 (da) | 2014-07-28 |
| ES2486300T3 (es) | 2014-08-18 |
| CA2628712C (en) | 2014-02-11 |
| WO2007055905A2 (en) | 2007-05-18 |
| WO2007055905A3 (en) | 2007-07-12 |
| SI2441461T1 (sl) | 2014-09-30 |
| IL232997A0 (en) | 2014-07-31 |
| ES2486300T4 (es) | 2020-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8088370B2 (en) | Compositions and methods of vascular injury repair | |
| EP2367432B1 (en) | Infarct area perfusion-improving composition | |
| US8637005B2 (en) | Compositions and methods of vascular injury repair | |
| US8425899B2 (en) | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency | |
| EP3170891B1 (en) | Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency | |
| HK1117874A (en) | Compositions and methods of vascular injury repair | |
| HK1117874B (en) | Compositions and methods of vascular injury repair | |
| HK1169327A (en) | Compositions and methods of vascular injury repair | |
| HK1169327B (en) | Compositions and methods of vascular injury repair | |
| HK1233305B (en) | Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency | |
| HK1233305A1 (en) | Compositions and uses for treating progressive myocardial injury due to a vascular insufficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |